Gastroesophageal reflux disease

Current Opinion in Gastroenterology

Volumn 18, Issue 4, 2002, Pages 447-453

  Sifrim, Daniel ^a   Zerbib, Frank ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; DUODENOGASTRIC REFLUX; ENDOSCOPY; ESOPHAGUS MOTILITY; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HIATUS HERNIA; HUMAN; LOWER ESOPHAGUS SPHINCTER; OBESITY; PATHOPHYSIOLOGY; REVIEW; STOMACH ACID SECRETION; STOMACH MOTILITY;

EID: 0036085146     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200207000-00009     Document Type: Review

References (68)

1. Gastric emptying: A contributory factor in gastro-oesophageal reflux activity?
2. Delayed gastric emptying and gastroesophageal reflux: A pathophysiologic relationship
3. Impact of delayed gastric emptying on the outcome of antireflux surgery
4. Gastric dysrhythmias occur in gastro-oesophageal reflux disease complicated by food regurgitation but not in uncomplicated reflux
5. Effect of caloric density of a meal on lower oesophageal sphincter motility and gastro-oesophageal reflux in healthy subjects
6. Effect of intragastric volume and osmolality on mechanisms of gastroesophageal reflux in children with gastroesophageal reflux disease
7. Integrated acidity and the pathophysiology of gastroesophageal reflux disease
8. Lessons learned from intragastric pH monitoring
9. Ambulatory gastric pH monitoring: Proper probe placement and normal values
10. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal
11. The importance of vacA, cagA, and iceA genotypes of Helicobacter pylori infection in peptic ulcer disease and gastroesophageal reflux disease
12. H. pylori: The bug is not all bad
13. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion
14. Review article: Is Helicobacter pylori relevant in the management of reflux disease?
15. The extent of duodenogastric reflux in gastro-oesophageal reflux disease
16. Gastro-oesophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis
17. Bile reflux gastritis and Barrett's oesophagus: Further evidence of a role for duodenogastro-oesophageal reflux?
18. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease
19. Role of diaphragmatic crura and lower esophageal sphincter in gastroesophageal reflux disease: Manometric and pH-metric study of small hiatal hernia
20. The crura and crura-sphincter pressure dynamics in patients with isolated upright and isolated supine reflux
21. Transient lower esophageal sphincter relaxations are no more frequent in patients with gastroesophageal reflux disease than in asymptomatic volunteers
22. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease
23. Prolonged measurement of lower oesophageal sphincter function in patients with intestinal metaplasia at the oesophagogastric junction
24. Transient lower oesophageal sphincter relaxations play an insignificant role in gastro-oesophageal reflux to the proximal oesophagus
25. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans
26. Provocation of transient lower esophageal sphincter relaxations by gastric distension with air
27. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD
28. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings
29. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole
30. Esophageal dysmotility and gastroesophageal reflux disease
31. Can symptoms predict esophageal motor function or acid exposure in gastroesophageal reflux disease? A comparison of esophageal manometric and twenty-four-hour pH parameters in typical and extraesophageal gastroesophageal reflux disease
32. Esophageal motility in reflux disease before and after fundoplication: A prospective, randomized, clinical, and manometric study
33. Sustained esophageal contraction: A motor correlate of heartburn symptom
34. No association between gall-stones and gastroesophageal reflux disease
35. Elevated body mass disrupts the barrier to gastroesophageal reflux
36. Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy
37. Gastric surgery is not a risk for Barrett's esophagus or esophageal adenocarcinoma
38. Intestinal metaplasia in patients with columnar lined esophagus is associated with high levels of duodenogastroesophageal reflux
39. Correlation of oesophageal acid exposure with Barrett's oesophagus length
40. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery
41. Proliferative activity in Barrett's esophagus before and after antireflux surgery
42. Pharyngeal pH monitoring in 222 patients with suspected laryngeal reflux
43. Association of laryngopharyngeal reflux disease and subglottic stenosis
44. Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer
45. Increased prevalence of gastroesophageal reflux symptoms in patients with COPD
46. Esophageal involvement and pulmonary manifestations in systemic sclerosis
47. Association of apnea and nonacid gastroesophageal reflux in infants: Investigations with the intraluminal impedance technique
48. Endoscopy-negative reflux disease
49. Nonerosive reflux disease: Current concepts and dilemmas
50. Non-erosive reflux disease: Part of the spectrum of gastrooesophageal reflux disease, a component of functional dyspepsia, or both?
51. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease
52. Decreasing oesophageal acid exposure in patients with GERD: A comparison of rabeprazole and omeprazole
53. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
54. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
55. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis; A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
56. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety
57. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease
58. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease
59. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial
60. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease
61. Step-down management of gastroesophageal reflux disease
62. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months
63. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial
64. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease
65. The cost of long term therapy for gastro-oesophageal reflux disease: A randomised trial comparing omeprazole and open antireflux surgery
66. Transoral, flexible endoscopic suturing for treatment of GERD: A multicenter trial
67. Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD
68. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD